Gunderson Dettmer represented client Tarsus Pharmaceuticals, a biopharmaceutical company, in its $100 million public offering. Tarsus Pharmaceuticals applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention.

Goldman Sachs & Co. LLC, BofA Securities, Guggenheim Securities, LLC and Oppenheimer & Co. acted as joint book-running managers for the offering.

The Gunderson Dettmer deal team was led by Ryan Gunderson and included Andrew Thorpe, Ilan Lovinsky, Leanne Gould and Benjamin A. Cohen-Kurzrock.

Companies
Tarsus Pharmaceuticals